Zoetis Inc. (NYSE:ZTS) Shares Bought by Lantz Financial LLC

Lantz Financial LLC raised its stake in Zoetis Inc. (NYSE:ZTS) by 18.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,236 shares of the company’s stock after acquiring an additional 194 shares during the period. Lantz Financial LLC’s holdings in Zoetis were worth $201,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently bought and sold shares of the company. Darwin Wealth Management LLC acquired a new stake in shares of Zoetis during the third quarter worth about $31,000. First Personal Financial Services acquired a new stake in shares of Zoetis during the third quarter worth about $33,000. Capital Performance Advisors LLP acquired a new stake in shares of Zoetis during the third quarter worth about $33,000. Dunhill Financial LLC boosted its stake in shares of Zoetis by 80.6% during the third quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock worth $33,000 after buying an additional 75 shares during the period. Finally, Quarry LP boosted its stake in shares of Zoetis by 273.2% during the second quarter. Quarry LP now owns 209 shares of the company’s stock worth $36,000 after buying an additional 153 shares during the period. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Trading Up 1.0 %

Shares of Zoetis stock opened at $168.63 on Friday. Zoetis Inc. has a 12-month low of $144.80 and a 12-month high of $200.53. The company has a current ratio of 3.69, a quick ratio of 2.27 and a debt-to-equity ratio of 1.26. The stock has a market cap of $76.08 billion, a PE ratio of 31.70, a price-to-earnings-growth ratio of 2.57 and a beta of 0.89. The company has a 50-day moving average of $170.10 and a two-hundred day moving average of $179.66.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Monday, November 4th. The company reported $1.58 earnings per share for the quarter, topping analysts’ consensus estimates of $1.46 by $0.12. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The business had revenue of $2.40 billion during the quarter, compared to analysts’ expectations of $2.29 billion. During the same period last year, the company posted $1.36 EPS. The company’s revenue was up 11.6% on a year-over-year basis. On average, research analysts anticipate that Zoetis Inc. will post 5.9 EPS for the current fiscal year.

Zoetis Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, January 21st will be paid a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.19%. This is a boost from Zoetis’s previous quarterly dividend of $0.43. The ex-dividend date is Tuesday, January 21st. Zoetis’s dividend payout ratio (DPR) is 37.59%.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the stock. Stifel Nicolaus decreased their target price on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. Leerink Partners assumed coverage on shares of Zoetis in a research note on Monday, December 2nd. They set an “outperform” rating and a $215.00 target price for the company. UBS Group assumed coverage on shares of Zoetis in a research report on Monday, December 9th. They issued a “neutral” rating and a $196.00 price objective for the company. Leerink Partnrs upgraded shares of Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. Finally, JPMorgan Chase & Co. raised their price objective on shares of Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a research report on Friday, October 11th. One research analyst has rated the stock with a hold rating, nine have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, Zoetis currently has a consensus rating of “Buy” and an average target price of $211.89.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.